Novartis today confirmed the plan to spin off 100% of its generic drugs arm Sandoz, with trading of the new company’s shares as well as ADRs (American Depositary Receipts...
As Novartis moves toward shedding generics subsidiary Sandoz, which it touts as a global leader in off-patent generic and biosimilar drugs, Sandoz has agreed a multi-year...
Sandoz, the generics and biosimilars arm of Swiss drugmaker Novartis, has signed a Memorandum of Understanding to build a biologics production plant in Lendava, Slovenia...
Sandoz, the generics arm of Swiss drugmaker Novartis, has announced plans to spend an additional €50 million on raising European manufacturing capacity for finished...
In advance of the planned spinoff of generics subsidiary Sandoz into a standalone generics producer, Novartis has announced it is closing one of the subsidiary’s US...
Novartis subsidiary Sandoz has launched a generic version of Combigan, the ocular hypertensiondrug made by AbbVie’s Allergan arm. The copy of the off-patent eye drops...
US private equity firms Blackstone and Carlyle may make a joint offer for the Novartis generics unit Sandoz, Bloomberg reports. With six other possible bidders seen as...
